Aβ Specific Neutra™ Antibody Products
Product listAmyloid beta (Aβ) is derived from non-amyloidogenic proteolysis of the amyloid precursor protein by β- / γ-secretase. Aβ has various forms such as Aβ monomer, Aβ oligomer, and Aβ amyloid plaques (see Figure 1). The deposition of Aβ is a critical event in the development of Alzheimer's disease (AD).
Fig.1 Structures of Aβ.1
Biological Functions of Aβ
The different forms of Aβ interact with different cell surface receptors via the extracellular domain and activate downstream pathways (figure 2). These pathways play pivotal roles in the progression of Alzheimer's disease.
Fig.2 Biological functions of Aβ and its pathogenesis of AD.1
Aβ-based Clinical Strategies
Inhibition of Aβ oligomerization is the main traditional strategy for the treatment of AD by overexpressing β-degrading enzymes, using small molecule inhibitors of β- / γ-secretase, or blocking amyloid channels. Currently, Aβ antibodies that hydrolyze specific aggregates or reduce amyloid loads have developed into novel immunotherapy approaches for AD.
Table 1 provides some biological antibodies targeting Aβ and their ideal immunotherapy effects such as plaque clearance and reduced neurotoxicity.
Tab. 1 Aβ-based immunotherapies for the treatment of AD.2
Creative Biolabs offers anti-Aβ antibodies that can be applied in all kinds of immunoassays including ELISA, IHC, and functional assays. These antibodies have good specificity to Aβ and are useful for the scientific research of the pathogenesis and treatment of AD.
REFERENCE
- Chen, Guo-fang, et al. "Amyloid beta: structure, biology and structure-based therapeutic development." Acta Pharmacologica Sinica 38.9 (2017): 1205-1235.
